India’s HPV Vaccine Cervavac Gets WHO Safety Nod: What It Means for Cervical Cancer Prevention

India has achieved an important milestone in the fight against cervical cancer with Cervavac, the country’s indigenously developed Human Papillomavirus (HPV) vaccine, receiving prequalification from the World Health Organisation (WHO).

Developed by the Serum Institute of India in collaboration with the Department of Biotechnology and the Bill & Melinda Gates Foundation, Cervavac is a gender-neutral quadrivalent HPV vaccine. It targets four HPV types: 6, 11, 16 and 18.

WHO prequalification is significant because it confirms that a vaccine has met international standards for safety, quality and efficacy. It also allows the vaccine to be procured by United Nations agencies, potentially making it easier for countries to access the product.

Why Is HPV Vaccination Important?

Human papillomavirus is a common viral infection that can affect both men and women. Persistent infection with certain high-risk HPV types can lead to cervical cancer and several other cancers.

HPV vaccination is considered an important preventive measure because it works before an individual is exposed to the virus. Vaccination is therefore generally most effective when given during adolescence, before exposure to HPV through sexual activity.

Cervical cancer remains a major public health concern in India. Vaccination, regular screening and timely treatment of precancerous changes are all important parts of prevention.

What Does Cervavac Protect Against?

Cervavac targets HPV types 6, 11, 16 and 18. HPV 16 and 18 are among the high-risk types associated with cervical cancer, while types 6 and 11 are associated with most cases of genital warts.

Because Cervavac is gender-neutral, its potential public-health relevance extends beyond cervical cancer prevention among women.

What Does WHO Prequalification Mean?

WHO prequalification does not mean that vaccination eliminates every risk of HPV infection or cancer. Instead, it confirms that the vaccine meets WHO requirements for quality, safety and efficacy.

The decision is particularly relevant for global vaccination programmes because countries and international organisations can use WHO-prequalified vaccines when planning procurement.

What Should Parents Know?

Parents should understand that HPV vaccination is a preventive vaccine rather than a treatment for an existing HPV infection.

The appropriate vaccination schedule depends on age, health status and national recommendations. Parents should therefore discuss the recommended schedule with a qualified healthcare professional.

Vaccination should also not replace cervical cancer screening. Even vaccinated women may need screening according to national guidelines because vaccines do not protect against every cancer-causing HPV type.

The Bigger Picture

Cervavac’s WHO prequalification represents an important step for India’s vaccine manufacturing and public-health capabilities.

For individuals, however, the larger message is straightforward: HPV vaccination, appropriate screening and awareness can work together to reduce the burden of HPV-related disease.

As India expands preventive healthcare, improving access to vaccination and ensuring people receive accurate information will remain essential.